secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001437749-25-037255
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences initiates thyroid cancer study with MD Anderson; IDE approved
-------------------------------------------------------------------------------

- FDA-approved IDE for first-in-human feasibility study of nPulse Vybrance system in papillary thyroid microcarcinoma.
- Study to commence early 2026, enroll 30 subjects at two sites, led by Dr. Victoria Banuchi at MD Anderson.
- Preclinical studies ongoing for anaplastic thyroid carcinoma, a rare cancer with <5% five-year survival rate.
- nPulse technology uses nonthermal nsPFA to limit scarring and damage to surrounding structures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925037255/0001437749-25-037255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925037255/plse20251208_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-037255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer